Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Exploring the Efficacy and Mechanism of Accelerated High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Obsessive-compulsive Disorder

11 november 2026 bijgewerkt door: Zhen Wang, Shanghai Mental Health Center

Exploring the Efficacy and Mechanism of Accelerated High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in the Treatment of Obsessive-compulsive Disorder: A Randomized Controlled Trial

This study will evaluate the therapeutic effects of accelerated high-definition transcranial direct current stimulation (HD-tDCS) as adjunct to pharmacotherapy in obsessive-compulsive disorder (OCD) patients, and the underlying neural mechanism by EEG, MRI, TMS-EEG and cognitive tasks.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The purpose of this study is to evaluate the clinical efficacy of accelerated high-definition transcranial direct current stimulation (HD-tDCS) targeting the orbitofrontal cortex (OFC) as an adjunct to pharmacotherapy in patients with obsessive-compulsive disorder (OCD), and to investigate its underlying neural mechanisms. Sixty patients with OCD receiving stable pharmacotherapy will be randomized to receive either active or sham HD-tDCS. Stimulation will be administered four times daily for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

Symptom severity will be assessed at baseline and upon completion of the HD-tDCS intervention. Assessments conducted throughout the study will include the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), the Clinical Global Impression (CGI) scale, the Obsessive-Compulsive Inventory-Revised (OCI-R), the Beck Depression Inventory-II (BDI-II), the Beck Anxiety Inventory (BAI), the Childhood Trauma Questionnaire (CTQ), a side-effect questionnaire, and other study-specified measures. A trained investigator will administer clinician-rated measures and oversee the completion of self-report questionnaires. Participants will also undergo magnetic resonance imaging (MRI), electroencephalography (EEG), and transcranial magnetic stimulation combined with EEG (TMS-EEG).

The Iowa Gambling Task will be administered at baseline, upon completion of the HD-tDCS intervention, and at the one-month follow-up after intervention completion to assess decision-making performance. The probabilistic reversal learning task will be administered at baseline, after the first HD-tDCS session, upon completion of the intervention, and at the one-month follow-up to assess reversal learning and cognitive flexibility under probabilistic uncertainty.

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Shanghai Mental Health Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 50 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Aged 18-50 years, of Han Chinese ethnicity, and right-handed.
  2. Meet the diagnostic criteria for obsessive-compulsive disorder (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
  3. Have a Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score ≥16.
  4. Have received at least one selective serotonin reuptake inhibitor (SSRI) at an adequate dose for an adequate duration. If currently taking medication, the dose must have been stable for at least eight weeks, and the medication type and dose must remain unchanged throughout the study.
  5. Have completed junior high school education or above.
  6. Provide informed consent.

Exclusion Criteria:

  1. Meet DSM-5 diagnostic criteria for a psychiatric disorder other than OCD, as assessed using the Structured Clinical Interview for DSM-5 (SCID-5).
  2. Have obsessive-compulsive symptoms severe enough to prevent completion of the required assessments and examinations.
  3. Have received electroconvulsive therapy (ECT), including modified ECT, within the past six months, or any other form of neuromodulation within the past two months.
  4. Have a serious medical condition or any medical condition that may precipitate seizures or increased intracranial pressure, including cardiovascular or respiratory diseases.
  5. Have a history of neurological disorders (e.g., epilepsy or stroke), traumatic brain injury, or brain surgery.
  6. Have implanted medical devices or materials, such as intracranial stents, cardiac pacemakers, coronary stents, or cochlear implants.
  7. Be at high risk of suicide.
  8. Be pregnant or planning to become pregnant in the near future.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: active HD-tDCS

Active cathodal high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

The HD-tDCS device will deliver a direct current of 2 mA for 20 minutes per session. The cathode will be positioned at Fp2 to target the right orbitofrontal cortex (OFC), with four return anodes placed at Fpz, AFz, AF4, and AF8, according to the international 10-10 EEG electrode placement system.

Sham-vergelijker: sham HD-tDCS

Sham high-definition transcranial direct current stimulation (HD-tDCS) targeting the right orbitofrontal cortex (OFC) will be administered four times daily at two-hour intervals for five consecutive days, followed by a two-day break and another five consecutive days of treatment, for a total of 40 sessions. Before each stimulation session, symptom provocation will be conducted by a research assistant who has completed standardized training.

In the sham stimulation group, the current will be gradually ramped up to 2 mA over approximately 30 seconds at the beginning of each session and ramped down to 0 mA over approximately 30 seconds at the end of each session.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale(Y-BOCS)
Tijdsspanne: About 6 weeks

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a semi-structured, clinician-rated instrument used to assess the severity of obsessive-compulsive symptoms. It comprises 10 items: five assessing obsessions and five assessing compulsions. Each item is rated on a five-point scale from 0 to 4, yielding a total score ranging from 0 to 40, with higher scores indicating greater symptom severity. Treatment response is defined as a reduction of at least 35% in the Y-BOCS total score from baseline to the end of the HD-tDCS intervention.

About 6 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The Beck Depression Inventory-II (BDI-II)
Tijdsspanne: About 6 weeks

It is a 21-item self-report measure scored on a 4-point Likert-type scale to summarize recent symptoms of depression.The higher the score, the higher the level of depression.

About 6 weeks
The Beck Anxiety Inventory (BAI)
Tijdsspanne: About 6 weeks

It is a 21-item self-report inventory that is used for measuring the severity of anxiety.The higher the score, the higher the level of anxiety.

About 6 weeks
Side-effect questionnaire
Tijdsspanne: About 6 weeks

It consists of ten commonly-reported side effects as well as an "other" category that allows participants to describe experiences/sensations not otherwise covered to rate the intensity of side effects.

About 6 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

25 oktober 2026

Primaire voltooiing (Geschat)

31 oktober 2029

Studie voltooiing (Geschat)

31 december 2029

Studieregistratiedata

Eerst ingediend

11 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 20240XJQ03DCS

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .